Rohto Dry-aid

The dosage of Povidone, Unspecified, when used as a plasma volume expander, is highly individualized and must be calculated by a healthcare professional based on the patient's body weight, the severity of fluid loss, and continuous hemodynamic monitoring.

• For Acute Hypovolemia: The initial infusion may range from 500 mL to 1,500 mL of a 3.5% or 4% solution. The rate of infusion is typically rapid in emergency settings but must be slowed once blood pressure stabilizes.
• Maximum Daily Dose: Clinical guidelines generally suggest not exceeding 20 mL per kilogram of body weight per day to prevent excessive accumulation of the polymer in the tissues.
• Ophthalmic Use: For dry eyes, the typical dosage is 1 to 2 drops in the affected eye(s) as needed, usually 3 to 4 times daily.

Povidone, Unspecified must be used with extreme caution in pediatric populations.

• Volume Expansion: Dosage is strictly calculated based on the child's weight (e.g., 10-15 mL/kg). Use in children is generally reserved for life-threatening situations where other volume expanders are unavailable or contraindicated.
• Ophthalmic Use: Safety and effectiveness in children for dry eye have not been extensively studied, though it is often used under specialist guidance.

Renal Impairment

In patients with impaired kidney function, the clearance of povidone molecules is significantly reduced. Because povidone is not metabolized, it can accumulate in the blood and tissues, leading to a condition known as 'povidone storage disease.' Healthcare providers will typically reduce the dose or avoid use entirely in patients with a GFR (Glomerular Filtration Rate) below 30 mL/min.

Hepatic Impairment

While the liver does not metabolize povidone, the reticuloendothelial cells in the liver may store the polymer. Patients with severe liver disease or cirrhosis should be monitored for signs of hepatosplenomegaly (enlargement of the liver and spleen) if povidone is administered.

Elderly Patients

Older adults are at a higher risk for fluid overload and congestive heart failure. Dosing should be conservative, often starting at the lower end of the range, with frequent monitoring of lung sounds and kidney function.

• Intravenous Administration: This must only be performed by trained medical personnel in a clinical setting. It is administered via a peripheral or central IV line. The solution should be inspected for particulate matter or discoloration before use.
• Ophthalmic Administration: If using povidone eye drops, wash your hands first. Tilt your head back, pull down the lower eyelid, and squeeze the drop into the pocket. Close your eye for 1-2 minutes. Do not let the dropper tip touch any surface, including your eye, to avoid contamination.
• Storage: Intravenous solutions should be stored at room temperature (15°C to 30°C or 59°F to 86°F) and protected from light. Do not freeze.

In a clinical setting for volume expansion, doses are administered as needed by medical staff; therefore, a missed dose is unlikely. For ophthalmic use, if you miss a dose, apply it as soon as you remember. If it is almost time for the next dose, skip the missed dose. Do not use double doses.

An overdose of intravenous povidone can lead to circulatory overload, characterized by:

• Shortness of breath (pulmonary edema)
• Rapid heart rate (tachycardia)
• High blood pressure (hypertension)
• Jugular venous distention (bulging neck veins)

In the event of an overdose, the infusion must be stopped immediately. Treatment is supportive and may include the administration of diuretics (water pills) to remove excess fluid and oxygen therapy. In cases of extreme accumulation, plasmapheresis (blood filtering) may be considered.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or administration method without medical guidance. Continuous monitoring is required during IV therapy.

When administered as an intravenous plasma volume expander, the most common side effects are related to the rapid shift in fluid balance. These may include:

• Transient Hypertension: A temporary increase in blood pressure as the vascular space fills.
• Dilutional Anemia: Because povidone expands the liquid part of the blood without adding red blood cells, the concentration of hemoglobin may temporarily drop.
• Localized Irritation: Redness or warmth at the site of the intravenous injection.
• Ophthalmic Stinging: For eye drop users, a brief burning or stinging sensation upon application is very common and usually lasts only seconds.

• Nausea and Vomiting: Some patients may experience mild gastrointestinal distress during or shortly after infusion.
• Fever and Chills: A mild pyrogenic (fever-inducing) reaction can occur, often resolving with supportive care.
• Urticaria (Hives): A mild allergic skin reaction characterized by itchy, raised welts.
• Headache: Often described as a dull pressure, likely due to changes in blood volume.

• Povidone Storage Disease (Thesaurosis): This is a rare condition where the povidone polymer accumulates in the body's tissues (liver, spleen, bone marrow, and skin) because it cannot be excreted. It can lead to organ enlargement and skin lesions.
• Acute Renal Failure: Particularly in patients who are already dehydrated or have pre-existing kidney disease, the high molecular weight of povidone can cause 'osmotic nephrosis.'
• Coagulopathy: Large doses may interfere with blood clotting factors, leading to an increased risk of bleeding or bruising.

> Warning: Stop taking Povidone, Unspecified and call your doctor immediately if you experience any of these serious symptoms.

• Anaphylaxis: A severe, life-threatening allergic reaction. Symptoms include swelling of the face, lips, or tongue; difficulty breathing; a sudden drop in blood pressure; and fainting.
• Pulmonary Edema: Fluid in the lungs. Signs include severe shortness of breath, gasping for air, and a cough that produces frothy sputum.
• Congestive Heart Failure: Signs include sudden weight gain, swelling in the ankles or legs (edema), and extreme fatigue.
• Severe Skin Eruptions: Rare cases of povidone-induced granulomas (small lumps) have been reported in patients receiving long-term therapy.

The long-term effects of povidone are primarily related to its persistence in the body. Because the human body lacks the enzymes to break down the vinyl backbone of the povidone polymer, high molecular weight fractions can remain in the reticuloendothelial system for years. This can lead to chronic inflammation in the storage organs. Patients who have received large volumes of povidone should be monitored for long-term changes in liver and spleen size. In ophthalmic use, long-term use is generally considered safe, but some patients may develop sensitivity to preservatives if they are present in the formulation.

No FDA black box warnings are currently issued for Povidone, Unspecified. However, it is important to recognize that its use as a volume expander has been largely superseded by other colloids and crystalloids due to the risk of tissue storage and potential interference with blood typing.

Report any unusual symptoms to your healthcare provider. If you suspect an allergic reaction, seek emergency care immediately.

Povidone, Unspecified is a potent agent that significantly alters the body's fluid dynamics. It should only be administered by healthcare professionals who can monitor vital signs, including blood pressure, heart rate, and urine output. Patients with a history of heart disease, kidney disease, or bleeding disorders must be identified before administration, as povidone can exacerbate these conditions.

There are currently no FDA black box warnings for Povidone, Unspecified. It is classified as 'Generally Recognized as Safe' (GRAS) when used as a pharmaceutical excipient in oral medications. However, its use as an intravenous therapeutic agent is subject to strict clinical oversight.

• Allergic Reactions / Anaphylaxis Risk: Although rare, povidone can trigger severe hypersensitivity reactions. Patients with a known allergy to povidone-iodine (Betadine) should inform their doctor, as they may also be sensitive to povidone alone.
• Fluid Overload: The primary risk of povidone therapy is the rapid expansion of blood volume beyond the heart's capacity to pump it. This is especially dangerous in patients with pre-existing heart failure or hypertension.
• Nephrotoxicity: High molecular weight povidone can accumulate in the renal tubules, potentially causing kidney damage. Adequate hydration (with crystalloids) is often necessary alongside povidone to protect the kidneys.
• Blood Typing Interference: Povidone can cause 'pseudo-agglutination' (clumping) of red blood cells. This can interfere with accurate blood typing and cross-matching. If you require a blood transfusion, the lab must be informed if you have recently received povidone.

Patients receiving intravenous povidone require intensive monitoring:

• Hemodynamic Monitoring: Frequent checks of blood pressure and heart rate.
• Renal Function: Monitoring of serum creatinine and blood urea nitrogen (BUN) levels, as well as hourly urine output.
• Electrolyte Balance: Regular blood tests to ensure that the shift in fluids has not caused dangerous imbalances in sodium or potassium.
• Hematocrit/Hemoglobin: To monitor for excessive dilution of the blood.

Intravenous povidone is used in acute clinical settings where driving is not possible. For ophthalmic povidone, your vision may be temporarily blurred immediately after applying the drops. Do not drive or operate machinery until your vision is clear.

There are no direct chemical interactions between povidone and alcohol. However, alcohol can cause dehydration and affect blood pressure, which may complicate the conditions for which povidone is being used. It is generally advised to avoid alcohol during recovery from acute illness.

When used as a volume expander, povidone is typically a short-term therapy. There is no 'withdrawal' syndrome associated with povidone. However, stopping the infusion too early in a shock state can lead to a dangerous relapse of low blood pressure. The discontinuation must be managed by a physician as they transition the patient to oral fluids or other therapies.

> Important: Discuss all your medical conditions with your healthcare provider before starting Povidone, Unspecified. Ensure they are aware of any history of kidney or heart problems.

There are no drugs that are strictly contraindicated with povidone based on chemical reactivity. However, povidone should not be mixed in the same intravenous line with:

• Whole Blood: Due to the risk of pseudo-agglutination (clumping of cells), povidone should not be infused simultaneously through the same line as a blood transfusion.

• Anticoagulants (e.g., Warfarin, Heparin): Povidone may have a mild inhibitory effect on platelet function and can dilute clotting factors. When combined with blood thinners, the risk of bleeding may increase. Close monitoring of the INR or PTT is required.
• Loop Diuretics (e.g., Furosemide): While diuretics are used to treat povidone-induced fluid overload, they can also increase the concentration of povidone in the kidneys, potentially increasing the risk of renal tubule damage.

• Other Colloids (e.g., Albumin, Dextran): Using multiple types of volume expanders simultaneously increases the risk of 'hyperoncotic' states, which can severely strain the kidneys and heart.
• Corticosteroids: Steroids can cause sodium and water retention, which may worsen the fluid overload risks associated with povidone administration.

There are no known significant interactions between povidone and specific foods. However, for patients receiving povidone for volume expansion, a low-sodium diet may be recommended following stabilization to help manage fluid balance.

• Garlic, Ginkgo, and Ginseng: These supplements are known to have mild anti-platelet effects. Combining them with the volume-expanding effects of povidone may slightly increase the risk of bruising or bleeding.
• St. John's Wort: While no direct interaction exists, St. John's Wort can affect the metabolism of many other drugs used in critical care settings.

• Erythrocyte Sedimentation Rate (ESR): Povidone can artificially increase the ESR, making it an unreliable marker for inflammation shortly after infusion.
• Blood Typing and Cross-matching: As mentioned, povidone can cause red blood cell clumping, which may lead to false-positive results in cross-matching tests. Always inform the laboratory if the patient has received povidone within the last 24-48 hours.
• Urinary Protein Tests: Povidone in the urine may interfere with certain colorimetric tests for proteinuria (protein in the urine), leading to inaccurate readings.

For each major interaction, the mechanism usually involves either a physical change in blood viscosity/osmotic pressure or an additive effect on the body's fluid management systems. Management typically involves adjusting the rate of infusion or choosing alternative fluids.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter eye drops or skin creams.

Povidone, Unspecified must NEVER be used in the following conditions:

1. 1Known Hypersensitivity: Any previous allergic reaction to povidone or povidone-iodine is an absolute contraindication. The risk of life-threatening anaphylaxis is too high.
2. 2Severe Congestive Heart Failure (CHF): In patients whose hearts cannot handle an increase in blood volume, povidone can cause immediate and fatal pulmonary edema (fluid in the lungs).
3. 3Oliguric or Anuric Renal Failure: If a patient is not producing urine, they cannot excrete the povidone molecules. This leads to rapid accumulation and systemic toxicity.
4. 4Severe Pulmonary Edema: Administering a volume expander when the lungs are already filled with fluid will worsen the respiratory failure.

In these cases, the healthcare provider will perform a careful risk-benefit analysis:

• Bleeding Disorders: Because povidone can dilute clotting factors and affect platelets, it should be used cautiously in patients with hemophilia or severe thrombocytopenia (low platelets).
• Dehydration (without blood loss): In simple dehydration, crystalloids (like saline) are usually preferred. Using a colloid like povidone can pull too much water from the cells into the blood, causing cellular dehydration.
• Chronic Liver Disease: Due to the risk of the substance being stored in the liver's Kupfer cells, it should be used only if other options are unavailable.

Patients who are allergic to certain synthetic polymers used in other medical devices or medications may have a cross-sensitivity to povidone. Specifically, those with 'Povidone Allergy' should avoid povidone-iodine antiseptics and medications that use povidone as an excipient (though the small amounts in tablets are rarely a problem compared to IV use).

> Important: Your healthcare provider will evaluate your complete medical history, including any history of asthma or allergies, before prescribing Povidone, Unspecified.

Povidone, Unspecified is generally classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and there are no adequate and well-controlled studies in humans. It is not known whether povidone can cause fetal harm when administered to a pregnant woman. During pregnancy, povidone should be used only if clearly needed, such as in life-threatening hemorrhagic shock where no other volume expander is suitable. There is a theoretical risk that the osmotic shifts caused by povidone could affect placental blood flow. Healthcare providers will prioritize the stabilization of the mother's blood pressure, as maternal hypotension is a significant risk to the fetus.

It is not known whether povidone is excreted in human milk. Because many drugs are excreted in milk and the effects of povidone on a nursing infant are unknown, caution should be exercised. However, since povidone is not absorbed orally, any povidone the infant might ingest through breast milk would likely pass through their digestive system without being absorbed. Regardless, a risk-benefit assessment by a pediatrician is recommended if the mother requires povidone therapy.

The safety and effectiveness of Povidone, Unspecified as a plasma expander in children have not been established through large-scale clinical trials. Pediatric dosing is based on weight-based calculations derived from adult data. The primary concern in children is the risk of fluid overload, as their cardiovascular systems have less 'reserve' than adults. It is NOT approved for routine use in children and is reserved for emergency stabilization.

Elderly patients are at a significantly increased risk when receiving povidone. Age-related declines in kidney function (reduced GFR) mean that the polymer will stay in the circulation longer and is more likely to be stored in the tissues. Furthermore, the elderly have a higher prevalence of undiagnosed heart failure, making them extremely susceptible to pulmonary edema during volume expansion. Close monitoring of lung sounds (checking for 'crackles') and central venous pressure is essential in this population.

In patients with renal impairment, the clearance of the smaller povidone molecules is delayed. This increases the oncotic pressure for a longer duration than intended and increases the risk of 'osmotic nephrosis'—a condition where the kidney cells become swollen and dysfunctional. Dosing must be strictly limited, and in many cases, povidone is avoided in favor of crystalloids or smaller-molecule colloids.

While the liver is not the primary route of elimination, povidone is taken up by the liver's immune cells. In patients with cirrhosis or hepatitis, this accumulation could theoretically worsen organ function or lead to splenomegaly (enlarged spleen). No specific dose adjustment formulas exist, but clinical monitoring for abdominal distention or pain is warranted.

> Important: Special populations require individualized medical assessment. Always inform your medical team about your pregnancy status or any chronic organ conditions.

Povidone, Unspecified acts as a colloid-osmotic agent. Its molecular structure consists of long chains of 1-vinyl-2-pyrrolidone. When these chains are present in the blood, they cannot cross the capillary endothelium. This creates a concentration gradient that draws water from the interstitial fluid into the plasma via osmosis. Unlike crystalloids (like normal saline), which quickly distribute throughout the entire body's water, povidone remains in the blood vessels, providing a more efficient and rapid expansion of the effective circulating volume. It does not bind to specific receptors; its 'target' is the physical balance of fluid between the blood and the tissues.

• Onset of Effect: The volume-expanding effect is almost immediate upon intravenous infusion.
• Duration of Effect: The effect typically lasts for 4 to 12 hours, depending on the molecular weight distribution of the specific povidone product used.
• Hemodynamic Response: A successful response is indicated by an increase in mean arterial pressure (MAP), a decrease in heart rate, and an improvement in urine output.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IV) / <1% (Oral) |

| Protein Binding | Minimal |

| Half-life | 4-20 hours (renal phase); weeks (storage phase) |

| Tmax | Immediate (IV) |

| Metabolism | None |

| Excretion | Renal (95% of small molecules), Fecal (if oral) |

• Molecular Formula: (C6H9NO)n
• Molecular Weight: Varies (typically 10,000 to 50,000 Daltons for medical use)
• Solubility: Highly soluble in water and many organic solvents.
• Structure: A linear polymer of N-vinylpyrrolidone. The 'K-value' (e.g., K-30) represents the mean molecular weight and viscosity of the polymer.

Povidone belongs to the Plasma Volume Expander class. Related medications include human albumin, hydroxyethyl starch (HES), and dextran. Unlike albumin, povidone is synthetic and carries no risk of viral transmission, but unlike crystalloids, it has a higher risk of tissue accumulation.